- Codiak BioSciences Inc (NASDAQ:CDAK) voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and will seek to pursue a sale process for its assets.
- The company began a marketing process ahead of the Chapter 11 filing to determine the level of market interest and is in ongoing discussions with several parties.
- The company expects to consummate a sale of the entire business or its core assets.
- Codiak BioSciences’ executive management team, including the CEO, CFO, Chief Medical Officer, and Chief Scientific Officer, will depart effective April 7.
- Douglas Williams (CEO) will remain on the Board.
- Konstantin Konstantinov, (Chief Technology Officer) will remain with the company.
- In August, the company announced a reprioritization of its clinical and research initiatives, accelerating discussions related to potential strategic corporate and program-based partnerships and restructuring operations to support a streamlined set of priorities.
- Codiak BioSciences also raised $20 million via equity in September last year.
- Price Action: CDAK shares are down 54.40% at $0.20 on the last check Monday.
Codiak BioSciences Files For Chapter 11 Bankruptcy
Codiak BioSciences Inc (NASDAQ:CDAK) voluntarily filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy…
Related Posts
3 Minutes To Boost Your Earnings: 3 High-Yielding Dividend Stocks In Real Estate Sector From Wall Street’s Most Accurate Analysts
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Merger-Bound Triton Records Mixed Q2 Performance, Declares Quarterly Dividends
Triton International Ltd (NYSE: TRTN) reported a Q2 FY23 total leasing revenue of $386.5 million, missing the